Riikka Siitonen1, Emilia Peuhu2,3, Anu Autio1, Heidi Liljenbäck1,4, Elina Mattila2, Olli Metsälä1, Meeri Käkelä1, Tiina Saanijoki1, Ingrid Dijkgraaf5, Sirpa Jalkanen6, Johanna Ivaska2,7, Anne Roivainen8,4,9. 1. Turku PET Centre, University of Turku, Turku, Finland. 2. Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland. 3. FICAN West Cancer Research Laboratory, University of Turku and Turku University Hospital, Turku, Finland. 4. Turku Center for Disease Modeling, University of Turku, Turku, Finland. 5. Department of Biochemistry, University of Maastricht, Maastricht, the Netherlands. 6. MediCity Research Laboratory, University of Turku, Turku, Finland. 7. Department of Biochemistry, University of Turku, Turku, Finland; and. 8. Turku PET Centre, University of Turku, Turku, Finland anne.roivainen@utu.fi. 9. Turku PET Centre, Turku University Hospital, Turku, Finland.
Abstract
Shank-associated RH domain-interacting protein (SHARPIN) is a cytosolic protein that plays a key role in activation of nuclear factor κ-light-chain enhancer of activated B cells and regulation of inflammation. Furthermore, SHARPIN controls integrin-dependent cell adhesion and migration in several normal and malignant cell types, and loss of SHARPIN correlates with increased integrin activity in mice. Arginyl-glycyl-aspartic acid (RGD), a cell adhesion tripeptide motif, is an integrin recognition sequence that facilitates PET imaging of integrin upregulation during tumor angiogenesis. We hypothesized that increased integrin activity due to loss of SHARPIN protein would affect the uptake of αvβ3-selective cyclic, dimeric peptide 68Ga-DOTA-E[c(RGDfK)]2, where E[c(RGDfk)]2 = glutamic acid-[cyclo(arginyl-glycyl-aspartic acid-D-phenylalanine-lysine)], both in several tissue types and in the tumor microenvironment. To test this hypothesis, we used RGD-based in vivo PET imaging to evaluate wild-type (wt) and SHARPIN-deficient mice (Sharpin cpdm , where cpdm = chronic proliferative dermatitis in mice) with and without melanoma tumor allografts. Methods: Sharpin cpdm mice with spontaneous null mutation in the Sharpin gene and their wt littermates with or without B16-F10-luc melanoma tumors were studied by in vivo imaging and ex vivo measurements with cyclic-RGD peptide 68Ga-DOTA-E[c(RGDfK)]2 After the last 68Ga-DOTA-E[c(RGDfK)]2 peptide PET/CT, tumors were cut into cryosections for autoradiography, histology, and immunohistochemistry. Results: The ex vivo uptake of 68Ga-DOTA-E[c(RGDfK)]2 in the mouse skin and tumor was significantly higher in Sharpin cpdm mice than in wt mice. B16-F10-luc tumors were detected 4 d after inoculation, without differences in volume or blood flow between the mouse strains. PET imaging with 68Ga-DOTA-E[c(RGDfK)]2 peptide at day 10 after inoculation revealed significantly higher uptake in the tumors transplanted into Sharpin cpdm mice than in wt mice. Furthermore, tumor vascularization was increased in the Sharpin cpdm mice. Conclusion: Sharpin cpdm mice demonstrated increased integrin activity and vascularization in B16-F10-luc melanoma tumors, as demonstrated by RGD-based in vivo PET imaging. These data indicate that SHARPIN, a protein previously associated with increased cancer growth and metastasis, may also have important regulatory roles in controlling the tumor microenvironment.
Shank-associated RH domain-interacting protein (SHARPIN) is a cytosolic protein that plays a key role in activation of nuclear factor κ-light-chain enhancer of activated B cells and regulation of inflammation. Furthermore, SHARPIN controls integrin-dependent cell adhesion and migration in several normal and malignant cell types, and loss of SHARPIN correlates with increased integrin activity in mice. Arginyl-glycyl-aspartic acid (RGD), a cell adhesion tripeptide motif, is an integrin recognition sequence that facilitates PET imaging of integrin upregulation during tumor angiogenesis. We hypothesized that increased integrin activity due to loss of SHARPIN protein would affect the uptake of αvβ3-selective cyclic, dimeric peptide 68Ga-DOTA-E[c(RGDfK)]2, where E[c(RGDfk)]2 = glutamic acid-[cyclo(arginyl-glycyl-aspartic acid-D-phenylalanine-lysine)], both in several tissue types and in the tumor microenvironment. To test this hypothesis, we used RGD-based in vivo PET imaging to evaluate wild-type (wt) and SHARPIN-deficientmice (Sharpin cpdm , where cpdm = chronic proliferative dermatitis in mice) with and without melanoma tumor allografts. Methods:Sharpin cpdm mice with spontaneous null mutation in the Sharpin gene and their wt littermates with or without B16-F10-luc melanoma tumors were studied by in vivo imaging and ex vivo measurements with cyclic-RGD peptide 68Ga-DOTA-E[c(RGDfK)]2 After the last 68Ga-DOTA-E[c(RGDfK)]2 peptide PET/CT, tumors were cut into cryosections for autoradiography, histology, and immunohistochemistry. Results: The ex vivo uptake of 68Ga-DOTA-E[c(RGDfK)]2 in the mouse skin and tumor was significantly higher in Sharpin cpdm mice than in wt mice. B16-F10-luc tumors were detected 4 d after inoculation, without differences in volume or blood flow between the mouse strains. PET imaging with 68Ga-DOTA-E[c(RGDfK)]2 peptide at day 10 after inoculation revealed significantly higher uptake in the tumors transplanted into Sharpin cpdm mice than in wt mice. Furthermore, tumor vascularization was increased in the Sharpin cpdm mice. Conclusion:Sharpin cpdm mice demonstrated increased integrin activity and vascularization in B16-F10-luc melanoma tumors, as demonstrated by RGD-based in vivo PET imaging. These data indicate that SHARPIN, a protein previously associated with increased cancer growth and metastasis, may also have important regulatory roles in controlling the tumor microenvironment.
Authors: Daphne Lobeek; Gerben M Franssen; Michelle T Ma; Hans-Jürgen Wester; Clemens Decristoforo; Wim J G Oyen; Otto C Boerman; Samantha Y A Terry; Mark Rijpkema Journal: J Nucl Med Date: 2018-04-06 Impact factor: 10.057
Authors: Antonella Zannetti; Silvana Del Vecchio; Francesca Iommelli; Annarita Del Gatto; Stefania De Luca; Laura Zaccaro; Angela Papaccioli; Jvana Sommella; Mariarosaria Panico; Antonio Speranza; Paolo Grieco; Ettore Novellino; Michele Saviano; Carlo Pedone; Marco Salvatore Journal: Clin Cancer Res Date: 2009-08-11 Impact factor: 12.531
Authors: R E Seymour; M G Hasham; G A Cox; L D Shultz; H Hogenesch; D C Roopenian; J P Sundberg Journal: Genes Immun Date: 2007-05-31 Impact factor: 2.676
Authors: Arghavan Jahandideh; Mia Ståhle; Jenni Virta; Xiang-Guo Li; Heidi Liljenbäck; Olli Moisio; Juhani Knuuti; Anne Roivainen; Antti Saraste Journal: Front Med (Lausanne) Date: 2021-12-15